Do I need an in-person exam for Wegovy in Illinois?

If you’ve been considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss, you might be wondering: Can I actually get these prescribed through telehealth? The short answer is yes—in most cases, you can legally obtain these medications through a virtual visit with a licensed healthcare provider.

As the demand for effective weight loss treatments has surged, so has access to telehealth services that can evaluate, prescribe, and monitor your progress—all from the comfort of your home. But the rules vary significantly by state, and understanding what’s required in your location is crucial to getting safe, legitimate care.

This comprehensive guide breaks down everything you need to know about getting weight loss medications through telehealth in 2025, including federal regulations, state-specific requirements, provider qualifications, and what to watch out for when choosing a telehealth service.

Understanding Federal Telehealth Rules for Weight Loss Medications

The Key Legal Distinction: Controlled vs. Non-Controlled Medications

Here’s the most important thing to understand: GLP-1 medications like Wegovy (semaglutide), Ozempic (semaglutide), and Mounjaro (tirzepatide) are not controlled substances. This matters because federal law—specifically the Ryan Haight Act—only requires an in-person examination before prescribing controlled medications via telehealth.

Since weight loss medications in the GLP-1 class are unscheduled drugs, they can be prescribed via telehealth under federal law without any mandatory in-person visit. This has been true even before the COVID-19 pandemic and remains the case today.

What About the DEA’s COVID-Era Telehealth Flexibilities?

You may have heard about temporary DEA rules allowing telehealth prescribing during the pandemic. While these flexibilities have been extended through December 31, 2025, they primarily affect controlled substances like Adderall, anxiety medications, and pain medications—not GLP-1 weight loss drugs.

The DEA and HHS announced in November 2024 that the telemedicine flexibilities for controlled substances would continue through the end of 2025, giving regulators more time to develop permanent rules. However, for patients seeking weight loss medications, these extensions don’t change anything—your access to GLP-1 drugs through telehealth was never restricted at the federal level.

The Bottom Line on Federal Rules

Under federal law, a licensed healthcare provider can evaluate you via video consultation and electronically send a prescription for Wegovy, Ozempic, or Mounjaro to your pharmacy—as long as they establish a valid patient-provider relationship and you meet the medical criteria for treatment.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-Specific Requirements: Where the Real Differences Lie

While federal law allows telehealth prescribing of weight loss medications, state laws add their own layers of requirements. Some states are very permissive, while others impose additional safeguards like mandatory in-person exams or follow-up schedules.

States Requiring an Initial In-Person Exam

Several states require that your first medical evaluation occur in person before you can continue treatment via telehealth:

Arkansas has some of the strictest telemedicine regulations in the country. You must have an initial face-to-face examination with your provider before they can prescribe weight loss medications through telehealth. Arkansas lawmakers have been considering proposals to ease these restrictions, but as of late 2025, the in-person requirement remains in effect.

Delaware requires an initial physical examination before telehealth prescribing of weight loss medications can begin. After that first visit, follow-up care can be conducted virtually.

Georgia mandates an in-person exam prior to prescribing obesity medications via telehealth. Interestingly, Georgia recently expanded prescribing authority—as of July 2024, nurse practitioners and physician assistants can now prescribe Schedule II controlled substances with physician delegation, though this doesn’t affect GLP-1 drugs (which aren’t controlled).

Mississippi expects an initial in-person evaluation for weight management therapy. The state is also considering legislation to grant nurse practitioners full practice authority, which could expand access to telehealth weight loss services in the future.

New Jersey has particularly comprehensive requirements. Before prescribing any weight loss medication, providers must conduct a thorough initial evaluation that includes a physical exam, laboratory tests, psychological screening, and documentation of a personalized diet and exercise plan. This evaluation must happen before treatment begins, though subsequent follow-ups can be virtual.

North Dakota requires a hands-on initial evaluation for weight loss treatment, per state medical board guidance. After the baseline assessment, telehealth follow-ups are permitted.

South Carolina mandates an initial in-person visit and requires periodic evaluations throughout treatment. Providers must follow a written protocol when prescribing weight loss medications.

Texas generally expects an in-person examination before prescribing weight loss medications, consistent with the state’s strict oversight of medical practice. Texas also maintains tight control over prescriptive authority—nurse practitioners must have a physician delegation agreement and cannot practice independently.

Virginia requires providers to perform an initial physical examination, laboratory work, and create a documented diet and exercise plan before prescribing any weight loss drug. Additionally, Virginia mandates a follow-up visit within 30 days of starting therapy and regular monitoring thereafter.

States With No In-Person Requirement

Many states allow you to receive weight loss medication prescriptions entirely through telehealth, with no mandatory in-person visits:

California explicitly permits telehealth examinations to establish the patient-provider relationship. A virtual consultation is legally sufficient to prescribe GLP-1 medications. California also has full independent practice authority for experienced nurse practitioners, expanding access to care.

Connecticut has permanent telehealth laws that don’t require in-person exams for weight loss prescriptions. However, the state does mandate that obesity treatment include behavioral counseling and a documented diet and exercise plan alongside medication.

Illinois allows full telehealth prescribing without in-person requirements. The state requires all prescriptions to be submitted electronically (a rule in place since 2023), which actually streamlines the telehealth process.

New York permits complete telehealth-based care for weight loss medications. The state has been a pioneer in telemedicine and allows nurse practitioners to practice independently after gaining experience.

Pennsylvania has no in-person mandate for GLP-1 prescriptions via telehealth. However, nurse practitioners still operate under physician collaboration agreements, as full practice authority regulations have not yet been finalized.

Washington is one of the most telehealth-friendly states, with no in-person requirements for weight loss medication prescribing. The state also has full independent practice for nurse practitioners. Worth noting: Washington’s My Health My Data Act (enacted in 2023) imposes strict privacy requirements on telehealth providers handling sensitive health information like weight and obesity data.

States With Special Monitoring Requirements

Florida allows telehealth prescribing but has specific conditions: patients must have a BMI of 30 or higher (or 27+ with comorbidities like diabetes or hypertension), and providers must schedule follow-up visits at least once every three months during treatment. These visits can be conducted via telehealth, but the regular monitoring requirement is legally mandated.

Utah encourages an initial in-person baseline evaluation but doesn’t strictly require it by law. The state recently expanded nurse practitioner autonomy (as of 2023), making telehealth more accessible.

Who Can Prescribe Weight Loss Medications via Telehealth?

Physicians (MDs and DOs)

All states allow licensed physicians to prescribe GLP-1 weight loss medications through telehealth, provided they’re licensed in the state where you’re located. This is straightforward and universal.

Nurse Practitioners (NPs)

Nurse practitioners can prescribe weight loss medications in every state, but their level of autonomy varies significantly:

Full Practice Authority States: In 34 states plus Washington D.C., nurse practitioners can practice independently without physician oversight once they meet experience requirements (typically 2-3 years of collaboration). These states include California, New York, Washington, Arizona, Colorado, Connecticut, Hawaii, Idaho, Maryland, Massachusetts, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oregon, Rhode Island, Utah, Vermont, and Wyoming, among others.

Collaborative Practice States: States like Florida, Georgia, Illinois, Pennsylvania, South Carolina, and Texas require nurse practitioners to have a collaboration agreement or supervisory arrangement with a physician. In these states, you might see an NP for your telehealth visit, but they’re practicing under a collaborative protocol.

Recent Expansions: Georgia made headlines in 2024 by allowing NPs and PAs to prescribe Schedule II controlled substances with physician delegation—the first time they could do so in that state. Indiana and Michigan also granted full practice authority to NPs in 2024.

Physician Assistants (PAs)

Physician assistants can prescribe weight loss medications in all states, but they typically require some form of physician supervision or collaboration agreement. The degree of autonomy varies, with some states allowing PAs significant independence in their practice while others maintain closer oversight.

What This Means for Your Telehealth Experience

When you connect with a telehealth weight loss service, you might meet with an MD, DO, NP, or PA depending on the state you’re in and the provider network. This is completely normal and legal—as long as the provider is appropriately licensed and credentialed in your state.

At Klarity Health, all providers are fully licensed in the states where they practice and operate within their scope of practice. You can feel confident that whether you see a physician or nurse practitioner, you’re receiving care from a qualified professional who can legally prescribe your medication.

What Medications Can You Get Through Telehealth?

Wegovy (Semaglutide 2.4mg)

Status: FDA-approved specifically for chronic weight management
Telehealth Eligible: ✅ Yes, in all states (state-specific rules apply)
Typical Supply: 30 days initially, up to 90 days once stable

Wegovy is the FDA-approved formulation of semaglutide for weight loss. It’s indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol.

Important: The FDA ended the shortage designation for Wegovy in 2025 and effectively banned most compounded versions of semaglutide. You should only receive brand-name Wegovy from a licensed pharmacy—not compounded alternatives from online sources.

Ozempic (Semaglutide 0.5-1mg)

Status: FDA-approved for type 2 diabetes; used off-label for weight loss
Telehealth Eligible: ✅ Yes, with proper documentation
Typical Supply: 30 days

Ozempic contains the same active ingredient as Wegovy (semaglutide) but is approved for treating type 2 diabetes. Many providers prescribe it off-label for weight loss, particularly when Wegovy is unavailable or insurance doesn’t cover it.

When prescribed off-label, your telehealth provider must document the medical rationale and obtain your informed consent. Legitimate providers will discuss why they’re recommending Ozempic for weight loss and explain the off-label nature of this use.

Mounjaro (Tirzepatide) / Zepbound

Status: Mounjaro approved for diabetes; Zepbound approved for obesity
Telehealth Eligible: ✅ Yes, in most states
Typical Supply: 30-day titration packs

Tirzepatide is available as Mounjaro (for diabetes) and Zepbound (for obesity). This dual GIP/GLP-1 receptor agonist has shown impressive weight loss results in clinical trials.

Like Ozempic, Mounjaro can be prescribed off-label for weight loss with appropriate documentation. Zepbound, approved in late 2023, is the obesity-specific branded version.

How Telehealth Weight Loss Treatment Actually Works

The Initial Consultation

Your first appointment typically involves:

1. Comprehensive medical history: You’ll complete a detailed questionnaire about your health history, current medications, allergies, previous weight loss attempts, and any contraindications to GLP-1 therapy.

2. Live video consultation: You’ll meet with a licensed provider via secure video chat. They’ll review your history, discuss your weight loss goals, assess your eligibility, and explain how the medication works.

3. Physical measurements: You’ll provide your current weight and height (many services ask you to verify this with a photo or video). The provider will calculate your BMI to confirm you meet clinical criteria.

4. Lab work discussion: Depending on your state and medical history, your provider may require recent lab results (metabolic panel, A1C, thyroid function) or recommend you get labs before starting medication.

5. Informed consent: Your provider will explain potential side effects (nausea, constipation, diarrhea, risk of gallstones, etc.), contraindications, and the importance of lifestyle modifications alongside medication.

6. Prescription: If you’re a good candidate, your provider will electronically send your prescription to your chosen pharmacy.

Ongoing Monitoring and Follow-Up

Responsible telehealth programs don’t just hand you a prescription and disappear. You should expect:

• Regular check-ins: Typically every 4-6 weeks initially, then every 2-3 months once stable
• Dose adjustments: GLP-1 medications are titrated up gradually; your provider will increase your dose based on tolerance and response
• Side effect management: Discussion of any adverse effects and strategies to minimize them
• Progress tracking: Monitoring weight loss, improvements in comorbidities, and overall well-being
• Lifestyle coaching: Many programs include nutritional guidance and exercise recommendations

Some states legally mandate specific follow-up schedules (Florida requires visits every 3 months; Virginia requires a check-in within 30 days of starting), but even in states without such requirements, good medical practice dictates regular monitoring.

What Makes You a Good Candidate?

Legitimate telehealth providers screen carefully. You’re generally a good candidate if you:

• Have a BMI of 30 or higher (obesity)
• OR have a BMI of 27-29.9 with weight-related health conditions (diabetes, hypertension, high cholesterol, sleep apnea)
• Have attempted lifestyle modifications (diet and exercise) without sustained success
• Don’t have contraindications (history of medullary thyroid cancer, MEN2 syndrome, pregnancy or planning pregnancy, active gallbladder disease, severe gastroparesis, history of pancreatitis)
• Are willing to commit to lifestyle changes alongside medication
• Can safely self-administer injections or have someone who can help you

You’re probably not a good candidate if you:

• Only need to lose a few pounds for cosmetic reasons
• Have a BMI under 27 without health conditions
• Are pregnant, breastfeeding, or planning pregnancy soon
• Have certain thyroid or pancreatic conditions
• Have severe psychiatric conditions that could complicate treatment
• Cannot commit to regular follow-up

The Cost Factor: Insurance vs. Cash Pay

Insurance Coverage

Many insurance plans now cover GLP-1 medications for weight loss, though coverage varies widely:

• Medicare: Generally does not cover weight loss medications (though this may change with pending legislation)
• Medicaid: Coverage varies by state; some state Medicaid programs cover Wegovy, others don’t
• Commercial insurance: Coverage is expanding but often requires prior authorization and documentation of medical necessity

Klarity Health accepts major insurance plans and helps navigate the prior authorization process. Our transparent approach means you’ll know your coverage and costs upfront.

Cash Pay Options

For those without insurance coverage or facing high deductibles, cash-pay telehealth services offer an alternative. Pricing typically includes:

• Consultation fee: $50-200 per visit
• Medication cost: Highly variable depending on the drug, dose, and pharmacy
• Wegovy: $1,300-1,500/month without insurance
• Ozempic: $900-1,000/month without insurance
• Mounjaro/Zepbound: $1,000-1,200/month without insurance

Some telehealth platforms negotiate discounted pharmacy rates or offer bundled pricing. Klarity Health provides transparent pricing for both insured and cash-pay patients, with no hidden fees.

Beware of Suspiciously Low Prices

If you see offers for GLP-1 medications at a fraction of typical costs, be cautious. You might be dealing with:

• Compounded medications: As of May 2025, the FDA banned most compounded semaglutide products for weight loss. Legitimate pharmacies should not be offering these.
• International sources: Importing medications from overseas is illegal and potentially dangerous—you can’t verify what you’re getting.
• Fraudulent operations: Some websites sell counterfeit or expired medications.

Stick with reputable telehealth providers that work with U.S.-licensed pharmacies dispensing FDA-approved medications.

Red Flags: How to Spot Questionable Telehealth Services

With the explosion in demand for weight loss medications, some less-than-scrupulous operators have entered the market. Watch out for these warning signs:

🚩 No Real Medical Evaluation

Legitimate providers require a thorough health assessment. Be skeptical if:

• You’re guaranteed a prescription before speaking with anyone
• The ‘evaluation’ is just a short questionnaire with no video consultation
• No one asks about your medical history or contraindications
• There’s no discussion of risks, benefits, and alternatives

🚩 Compounded or ‘Generic’ Semaglutide

Since the FDA removed semaglutide from the shortage list and banned routine compounding:

• You should receive brand-name Wegovy, Ozempic, or Mounjaro—not ‘generic semaglutide’
• Any service offering compounded versions is operating in a legal gray area at best
• Compounded products lack the quality control and FDA oversight of brand medications

🚩 No Follow-Up or Monitoring

Red flag if:

• The service doesn’t schedule follow-up appointments
• No one monitors your progress or adjusts your dose
• You’re left to figure out side effects on your own
• Refills are automatic without any provider check-in

🚩 Lack of Transparency

Be wary when:

• The service isn’t clear about who your provider is or their credentials
• There’s no physical address or clinic affiliation listed
• The website doesn’t specify which states they operate in
• Pricing is hidden or unclear until after you’ve signed up
• You’re asked to waive your rights or sign unusual consent forms

🚩 Pressure Tactics

Legitimate providers don’t use high-pressure sales tactics:

• Claims that you need to ‘act now’ or supplies will run out
• Aggressive upselling of supplements or additional products
• Promises of specific weight loss amounts (e.g., ‘lose 30 pounds in 30 days’)
• Dismissal of your concerns or questions

✅ What to Look For Instead

Choose a telehealth provider that:

• Requires a live video consultation with a licensed provider
• Clearly states their providers’ credentials and licensure
• Operates transparently in specific states
• Discusses risks, benefits, and alternatives thoroughly
• Schedules regular follow-up appointments
• Works with licensed U.S. pharmacies
• Provides clear, upfront pricing
• Emphasizes lifestyle changes alongside medication
• Has accessible customer service and medical support

Klarity Health checks all these boxes. Our licensed providers conduct thorough evaluations, provide ongoing monitoring, accept both insurance and cash payment, and maintain transparent pricing. We’re committed to safe, evidence-based weight loss treatment that prioritizes your health and wellbeing.

State Licensing and Interstate Practice

One often-overlooked aspect of telehealth is that providers must be licensed in the state where you’re physically located when receiving care.

How It Works

If you live in California, your telehealth provider must hold an active California medical license—even if their practice is based in New York. This can be complex for national telehealth companies, which is why many:

• Employ or contract with providers licensed in multiple states
• Participate in interstate licensure compacts
• Limit service to specific states where they have licensed providers

Interstate Compacts

Some states participate in compacts that streamline multi-state licensure:

• Interstate Medical Licensure Compact (IMLC): Allows physicians to obtain licenses in multiple states more easily
• Nurse Licensure Compact (NLC): Allows nurses (including NPs in some cases) to practice across state lines
• Psychology Interjurisdictional Compact (PSYPACT): For mental health providers

However, these compacts don’t eliminate licensing requirements—they just make the process easier.

What This Means for You

When choosing a telehealth service:

• Verify they operate in your state
• Confirm your provider is licensed in your state
• Understand that if you travel or move, you may need to switch providers

At Klarity Health, we operate in multiple states with providers licensed in each location. We’ll match you with a provider appropriately licensed to treat you based on where you live.

The Clinical Criteria: Who Actually Qualifies?

Understanding the medical criteria helps set realistic expectations about whether you’ll be prescribed weight loss medication.

BMI Requirements

The primary criterion is Body Mass Index (BMI):

• BMI ≥ 30: Qualifies for GLP-1 weight loss medication without additional conditions
• BMI 27-29.9: May qualify if you have at least one weight-related comorbidity:
• Type 2 diabetes or prediabetes
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease
• Fatty liver disease (NAFLD/NASH)

Previous Weight Loss Attempts

Most providers expect you’ve tried lifestyle modifications (diet and exercise) before medication. This doesn’t mean you need to have failed multiple formal programs, but you should demonstrate that:

• You’ve made genuine attempts to lose weight through caloric restriction and increased activity
• These attempts didn’t result in sustained weight loss or were impractical to maintain
• You’re willing to continue lifestyle modifications while on medication

Contraindications That May Disqualify You

Absolute contraindications (you cannot receive GLP-1 medications):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or planning pregnancy in the near future
• Breastfeeding

Relative contraindications (may disqualify depending on severity):

• History of pancreatitis
• Severe gastroparesis or delayed gastric emptying
• Active gallbladder disease
• Diabetic retinopathy (requires careful monitoring)
• History of severe hypoglycemia (if diabetic)
• Severe psychiatric conditions (eating disorders, severe depression)
• Renal impairment (kidney disease)

Special Considerations

Age: GLP-1 medications are FDA-approved for adults. Use in pediatric patients (12-17) exists for some formulations but requires additional considerations.

Pregnancy planning: You must discontinue GLP-1 medications at least 2 months before attempting conception. If you’re planning to get pregnant soon, these medications aren’t appropriate.

Other medications: Your provider will review all current medications to check for interactions, particularly if you’re on:

• Insulin or other diabetes medications (dosing may need adjustment)
• Oral medications that depend on gastric absorption (GLP-1s slow gastric emptying)

Safety and Side Effects: What to Expect

Understanding potential side effects helps you make an informed decision and prepare for treatment.

Common Side Effects (Very Common)

• Nausea: Often the most reported side effect, especially when starting or increasing dose. Usually improves over time.
• Diarrhea or constipation: GI effects are common as your digestive system adjusts.
• Decreased appetite: This is actually part of how the medication works, but can feel strange initially.
• Fatigue: Some people feel more tired, especially early in treatment.
• Headache: Usually mild and temporary.

Less Common But Notable Side Effects

• Vomiting: Less common than nausea but can occur, especially if you eat too much too quickly.
• Abdominal pain or discomfort: Usually mild but worth monitoring.
• Heartburn/reflux: The slower gastric emptying can worsen reflux in some people.
• Injection site reactions: Redness, itching, or discomfort at injection sites (usually mild).

Serious Side Effects (Rare But Important)

• Pancreatitis: Severe abdominal pain that radiates to the back. Seek immediate medical attention.
• Gallbladder problems: Rapid weight loss can increase gallstone risk. Symptoms include severe upper right abdominal pain.
• Hypoglycemia: Low blood sugar (mainly a concern if you also take diabetes medications).
• Kidney problems: Dehydration from vomiting/diarrhea can affect kidney function.
• Vision changes: Diabetic retinopathy can worsen (particularly in diabetic patients who lose weight quickly).
• Allergic reactions: Rare but possible (rash, itching, difficulty breathing).

FDA Boxed Warning

GLP-1 medications carry a boxed warning about thyroid C-cell tumors, based on animal studies. While this hasn’t been confirmed in humans, people with a personal or family history of medullary thyroid cancer or MEN2 syndrome should not take these medications.

Managing Side Effects

Your telehealth provider should discuss strategies to minimize side effects:

• Start at the lowest dose and titrate up slowly
• Eat smaller, more frequent meals
• Avoid high-fat and greasy foods
• Stay well-hydrated
• Take anti-nausea medication if needed
• Slow down eating and chew thoroughly

Privacy and Data Security in Telehealth

When you share sensitive health information about your weight, eating habits, and medical history online, privacy matters.

HIPAA Compliance

Legitimate telehealth providers must comply with the Health Insurance Portability and Accountability Act (HIPAA), which protects your health information. This means:

• Secure video platforms (not regular Zoom or FaceTime)
• Encrypted data transmission and storage
• Strict access controls on who can view your information
• Business associate agreements with any third parties

State Privacy Laws

Some states have additional privacy protections:

Washington’s My Health My Data Act (2023) imposes strict requirements on handling consumer health data, including weight and obesity information. Telehealth providers serving Washington residents must:

• Obtain explicit consent before collecting health data
• Provide clear disclosures about data use
• Allow consumers to access and delete their data
• Implement strong security safeguards

Similar laws are emerging in other states, pushing telehealth companies toward higher privacy standards.

What to Ask About Privacy

Before signing up with a telehealth service:

• How is my video consultation secured?
• Where is my health data stored?
• Who has access to my information?
• Will my data be sold or shared with third parties?
• Can I delete my account and data?
• What happens if there’s a data breach?

Klarity Health takes privacy seriously, using HIPAA-compliant platforms, encrypted data storage, and transparent privacy policies. We never sell your health information to third parties.

The Future of Telehealth Weight Loss Treatment

The regulatory landscape continues to evolve, generally in a direction that expands access while maintaining safety standards.

Federal Outlook

DEA Telehealth Rules: While current flexibilities for controlled substances expire December 31, 2025, signals suggest another extension or new permanent rules will prevent disruption. For GLP-1s (non-controlled), no changes are expected—telehealth prescribing will remain straightforward.

Congressional Action: The bipartisan TREATS Act, reintroduced in October 2025, would permanently allow certain telehealth prescribing of controlled medications without initial in-person exams. If passed, it would signal Congressional support for expanded telemedicine across the board.

Medicare Coverage: There’s ongoing advocacy to include weight loss medications in Medicare Part D coverage. If successful, this would dramatically expand access for seniors.

State Trends

Expanding NP Authority: More states are granting nurse practitioners full practice authority. Bills are pending in Mississippi, Pennsylvania, and other states that could expand telehealth provider networks.

Telehealth Parity Laws: Many states are enacting laws requiring insurance to cover telehealth visits the same as in-person visits, making virtual care more accessible.

Streamlined Licensing: Interstate compacts are growing, making it easier for providers to be licensed in multiple states and serve patients across broader geographic areas.

New Medications on the Horizon

Several new anti-obesity medications are in development or recently approved:

• Retatrutide (Eli Lilly): Triple agonist showing even better weight loss results in trials
• CagriSema (Novo Nordisk): Combination therapy in development
• Oral GLP-1s: Pills instead of injections (some already approved for diabetes, obesity versions coming)

As these medications reach the market, telehealth will likely remain a primary access point.

Why Klarity Health for Your Weight Loss Journey

If you’re considering telehealth for weight loss medication, Klarity Health offers several advantages:

Licensed Providers in Multiple States

We employ and contract with providers licensed in the states we serve, ensuring your care is legally compliant and appropriate for your location.

Comprehensive Evaluation

Our providers conduct thorough medical evaluations, discuss your goals and concerns, and ensure you’re a good candidate for medication—we never guarantee prescriptions without proper assessment.

Transparent Pricing

Whether you’re using insurance or paying cash, you’ll know your costs upfront. We accept major insurance plans and offer competitive cash-pay rates with no hidden fees.

Ongoing Support

Weight loss is a journey, not a one-time prescription. We provide regular follow-ups, dose adjustments, side effect management, and lifestyle coaching to support your success.

FDA-Approved Medications Only

We prescribe only brand-name, FDA-approved medications dispensed by licensed U.S. pharmacies—no compounded alternatives or questionable sources.

Flexible Access

With evening and weekend availability, we fit into your schedule. Our platform makes it easy to book appointments, message your provider, and manage your treatment.

Taking the Next Step

If you’ve been struggling with weight and wondering whether telehealth weight loss treatment is right for you, here’s what to do:

1. Check your state’s requirements using our guide above to understand any specific rules where you live.

2. Assess your eligibility based on BMI, health conditions, and contraindications.

3. Research providers carefully, looking for the green flags and avoiding the red flags we’ve outlined.

4. Schedule a consultation with a licensed provider who can evaluate your individual situation.

5. Prepare for your visit by gathering your medical history, current medications, and any relevant lab work.

At Klarity Health, we’re here to make your weight loss journey safer, more convenient, and more successful. Our licensed providers are available to answer your questions, conduct thorough evaluations, and provide the ongoing support you need to achieve sustainable weight loss.

Ready to get started? Schedule a consultation with Klarity Health today. Our providers will work with you to determine if GLP-1 medication is appropriate, help navigate insurance coverage, and create a personalized treatment plan that fits your life.

Telehealth has revolutionized access to effective weight loss treatment—making it more convenient than ever to get the help you need, where you are, on your schedule. With the right provider, proper medical oversight, and commitment to lifestyle changes, medications like Wegovy, Ozempic, and Mounjaro can be powerful tools in your weight loss journey.

Research Sources

This guide is based on current regulations and clinical guidelines as of December 2025. Key sources include:

1. DEA and HHS Announcement – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (www.dea.gov, November 15, 2024) – Official government release confirming federal telehealth rules for controlled substances through December 31, 2025.

2. Axios News – ‘COVID-era telehealth prescribing extended’ (www.axios.com, November 18, 2024) – Reliable news summary of DEA extension aligned with official DEA information.

3. McDermott Will & Emery Law Firm – ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025’ (www.mwe.com, November 18, 2024) – Expert legal analysis citing regulations and proposals, current as of 2024.

4. Goodwin Procter Law Firm – ‘The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (www.goodwinlaw.com, March 27, 2024) – Detailed healthcare law alert with citations to Florida, New Jersey, and Virginia state regulations.

5. Reuters – ‘Hims to cut 4% of workforce amid ban on weight-loss drug copies’ (www.reuters.com, May 30, 2025) – Factual reporting on FDA action ending compounded semaglutide products, confirming enforcement on compounded GLP-1 medications.

Verified as of December 17, 2025. Federal regulations for controlled substances remain temporary through December 31, 2025. State laws continue to evolve; patients should verify current requirements in their specific state. Non-controlled medications like GLP-1 agonists are not subject to the Ryan Haight Act’s in-person requirement under federal law.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid